View Older Stories View More Recent Stories

Mar 31, 2026 06:35AM Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'

Mar 26, 2026 05:34AM Wolfe Research Starts Structure Therapeutics (GPCR) at Peerperform

Mar 17, 2026 08:29AM Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital

Mar 17, 2026 06:46AM Structure Therapeutics (GPCR) PT Lowered to $100 at H.C. Wainwright

Mar 17, 2026 05:29AM Citizens Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)

Mar 16, 2026 12:32PM Stifel on Structure Therapeutics (GPCR): ACCESS-II data supports 'low and slow' strategy ahead of Ph3

Mar 16, 2026 11:51AM William Blair Reiterates Outperform Rating on Structure Therapeutics (GPCR): 'considerable market opportunity for aleniglipron'

Mar 16, 2026 10:32AM Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'

Mar 16, 2026 10:25AM RBC: 'Our focus for LLY remains on the pending Orfo approval and subsequent launch'

Mar 2, 2026 06:59AM Structure Therapeutics (GPCR) PT Raised to $114 at H.C. Wainwright

Feb 27, 2026 10:36AM Cantor: 'GPCR has a key near-term update which we think can move the stock higher again'

Feb 27, 2026 04:29AM Structure Therapeutics (GPCR) PT Lowered to $113 at Citizens Ahead of Readouts

Jan 26, 2026 05:52AM Structure Therapeutics (GPCR) call put ratio 4.8 calls to 1 put as share price near record high

Jan 22, 2026 10:53AM Structure Therapeutics (GPCR) call put ratio 1.5 calls to 1 put amid wide price movement

Jan 20, 2026 06:54AM Structure Therapeutics (GPCR) PT Raised to $140 at Guggenheim

Jan 14, 2026 03:05PM Structure Therapeutics (GPCR) call put ratio 9.6 calls to 1 put with a focus on January and February calls as share price up 6.5%

Jan 6, 2026 07:10AM Structure Therapeutics (GPCR) Reiterated at Overweight by Cantor Fitzgerald

Jan 6, 2026 04:25AM BMO Capital on Structure Therapeutics (GPCR): 'Licensing agreement with Genentech is not the large Pharma partnership that some Structure owners have been anxiously awaiting'

Jan 5, 2026 04:11PM Structure Therapeutics subsidiary licenses patents to Genentech for $100M

Dec 22, 2025 07:10AM Structure Therapeutics (GPCR) PT Raised to $90 at H.C. Wainwright

Dec 12, 2025 04:40AM Structure Therapeutics (GPCR) PT Raised to $120 at Citizens

Dec 9, 2025 05:53AM Structure Therapeutics (GPCR) call put ratio 1.3 calls to 1 put amid sharp rally

Dec 9, 2025 05:05AM Structure Therapeutics (GPCR) PT Raised to $100 at Citi, Removes Catalyst Watch

Dec 9, 2025 04:41AM Structure Therapeutics (GPCR) PT Raised to $130 at BMO Capital

Dec 9, 2025 04:40AM Structure Therapeutics (GPCR) PT Raised to $99 at Clear Street

Dec 8, 2025 04:57PM After-hours movers: NVIDIA, Toll Brothers, and more

Dec 8, 2025 04:02PM Structure Therapeutics (GPCR) PT Raised to $90 at Stifel

Dec 8, 2025 12:14PM Jefferies on Structure Therapeutics (GPCR): 'We think the topline data is compelling and believe it reinforces a Ph3 ready profile with best-in-class weight loss'

Dec 8, 2025 08:01AM Structure Therapeutics reports weight loss data for obesity drug candidate

Dec 2, 2025 09:21AM Stifel Reiterates Buy Rating on Structure Therapeutics (GPCR)

Nov 28, 2025 06:35AM H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

Nov 24, 2025 04:34AM Structure Therapeutics' (GPCR) 'Aleniglipron is Well Positioned' - Citizens

Nov 20, 2025 04:07AM BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)

Nov 10, 2025 08:05AM BMO Capital on Structure Therapeutics (GPCR): 'Year-End Readout Sets Key Inflection Point'

Nov 3, 2025 05:05AM Citi Opens 90-Day Upside Catalyst Watch on Structure Therapeutics (GPCR)

Oct 28, 2025 08:17AM Piper Sandler: 'Time Is Right to Own Structure Therapeutics (GPCR) Now'

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 8, 2025 04:09AM Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)

Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'

Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'

Sep 24, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

Sep 17, 2025 07:03AM Cantor Fitzgerald Reiterates Overweight Rating on Structure Therapeutics (GPCR)

Sep 17, 2025 04:14AM Citizens JMP Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)

Sep 8, 2025 06:53AM Cantor Fitzgerald Reiterates Overweight Rating on Structure Therapeutics (GPCR)

Aug 7, 2025 06:55AM Structure Therapeutics (GPCR) PT Lowered to $90 at Guggenheim

Aug 7, 2025 04:10AM Structure Therapeutics (GPCR) PT Lowered to $87 at Citizens JMP

Jul 30, 2025 04:51PM Clear Street Starts Structure Therapeutics (GPCR) at Buy

Jun 23, 2025 07:14AM Cantor Fitzgerald Reiterates Overweight Rating on Structure Therapeutics (GPCR)

Jun 23, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

Jun 23, 2025 04:48AM Citizens JMP Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)

View More Recent Stories View Older Stories